Inhibition of zinc metallopeptidases in cardiovascular disease - From unity to trinity, or duality?

Current Pharmaceutical Design

Volumn 15, Issue 31, 2009, Pages 3606-3621

  Dive, Vincent ^a   Chang, Cheng Fu ^b   Yiotakis, Athanasios ^c   Sturrock, Edward D ^b  

^a SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

ACE2; Angiotensin converting enzyme; Cardiovascular disease; Endothelin converting enzyme; Neutral endopeptidase; Vasopepidase inhibitor

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ARGININE; ASPARTIC ACID; ATRIAL NATRIURETIC FACTOR; BP 1137; CGS 35601; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALIN; FASIDOTRILAT; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; MLN 4760; NEURAL ENDOPEPTIDASE; NEURAL ENDOPEPTIDASE INHIBITOR; OMAPATRILAT; RHAMNOSE; RXP 400; RXP 403; RXP 4031; RXP 4032; RXP 404; RXP 407; RXPA 380; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC METALLOPROTEINASE INHIBITOR;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANGIONEUROTIC EDEMA; ANTIFIBROTIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME METABOLISM; ENZYME SUBSTRATE; HEART PROTECTION; HUMAN; HYDROPHOBICITY; HYPERTENSION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; LIGANDS; METALLOENDOPEPTIDASES; PROTEIN CONFORMATION; ZINC;

EID: 70449601972     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789271889     Document Type: Review

References (110)

1. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998; 9117: 1693-1697
2. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 1 (Suppl): 169S-73S.
3. Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004; 4: 499-509. (Pubitemid 39469033)
4. Beltrami L, Zingale LC, Carugo S, Cicardi M. Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it. Expert Opin Drug Saf 2006; 5: 643-649 (Pubitemid 44322882)
5. Semple PF. Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. J Hypertens Suppl 1995; 3: S17-S21.
6. Azizi M, Ezan E, Reny JL, Wdzieczak-Bakala J, Gerineau V, Menard J. Renal and metabolic clearance of N-acetyl-seryl aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans. Hypertension 1999; 3: 879-886 (Pubitemid 29140450)
7. Rousseau A, Michaud A, Chauvet MT, Lenfant M, Corvol P. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem 1995; 8: 3656-3661
8. Natesh R, Schwager SL, Sturrock ED, Acharya KR. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 2003; 6922: 551-554 (Pubitemid 36168450)
9. Rushworth CA, Guy JL, Turner AJ. Residues affecting the chloride regulation and substrate selectivity of the angiotensin-converting enzymes (ACE and ACE2) identified by site-directed mutagenesis. FEBS J 2008; 23: 6033-6042
10. Corradi HR, Chitapi I, Sewell BT, Georgiadis D, Dive V, Sturrock ED, et al. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380. Biochemistry 2007; 18: 5473-5478 (Pubitemid 46717270)
11. Watermeyer JM, Kroger WL, O'Neill HG, Sewell BT, Sturrock ED. Probing the basis of domain-dependent inhibition using novel ketone inhibitors of Angiotensin-converting enzyme. Biochemistry 2008; 22: 5942-5950
12. Corradi HR, Schwager SL, Nchinda AT, Sturrock ED, Acharya KR. Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. J Mol Biol 2006; 3: 964-974
13. Wei L, Clauser E, Alhenc-Gelas F, Corvol P. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem 1992; 19: 13398-13405
14. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin- converting enzyme 2 protects from severe acute lung failure. Nature 2005; 7047: 112-116 (Pubitemid 40966195)
15. Yamamoto K, Ohishi M, Katsuya T, Ito N, Ikushima M, Kaibe M, et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 2006; 4: 718-726 (Pubitemid 43740244)
16. Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H, Khokha R, et al. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 2006; 6: 1808-1820 (Pubitemid 43825302)
17. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 6891: 822-828 (Pubitemid 34670323)
18. Gurley SB, Allred A, Le TH, Griffiths R, Mao L, Philip N, et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 2006; 8: 2218-2225 (Pubitemid 44162331)
19. Tikellis C, Cooper ME, Bialkowski K, Johnston CI, Burns WC, Lew RA, et al. Developmental expression of ACE2 in the SHR kidney: a role in hypertension? Kidney Int 2006; 1: 34-41.
20. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 5: E1-9.
21. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 17: 14838-14843 (Pubitemid 34952556)
22. Guy JL, Jackson RM, Acharya KR, Sturrock ED, Hooper NM, Turner AJ. Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry 2003; 45: 13185-13192
23. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 43: 33238-33243 (Pubitemid 30808528)
24. Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T, et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem 2004; 17: 17996-18007 (Pubitemid 38560569)
25. Guy JL, Jackson RM, Jensen HA, Hooper NM, Turner AJ. Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis. FEBS J 2005; 14: 3512-3520
26. Dales NA, Gould AE, Brown JA, Calderwood EF, Guan B, Minor CA, et al. Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc 2002; 40: 11852-11853
27. Huentelman MJ, Zubcevic J, Hernandez Prada JA, Xiao X, Dimitrov DS, Raizada MK, et al. Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension 2004; 6: 903-906 (Pubitemid 39577419)
28. Rella M, Rushworth CA, Guy JL, Turner AJ, Langer T, Jackson RM. Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors. J Chem Inf Model 2006; 2: 708-716
29. Deaton DN, Graham KP, Gross JW, Miller AB. Thiol-based angiotensin-converting enzyme 2 inhibitors: P1′ modifications for the exploration of the S1′ subsite. Bioorg Med Chem Lett 2008; 5: 1681-1687
30. Deaton DN, Gao EN, Graham KP, Gross JW, Miller AB, Strelow JM. Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite. Bioorg Med Chem Lett 2008; 2: 732-737
31. Mores A, Matziari M, Beau F, Cuniasse P, Yiotakis A, Dive V. Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2. J Med Chem 2008; 7: 2216-2226
32. Dive V, Georgiadis D, Matziari M, Makaritis A, Beau F, Cuniasse P, et al. Phosphinic peptides as zinc metalloproteinase inhibitors. Cell Mol Life Sci 2004; 16: 2010-2019 (Pubitemid 39149891)
33. Kenny AJ, Fulcher IS. Microvillar endopeptidase, an enzyme with special topological features and a wide distribution. Ciba Found Symp 1983; 12-33.
34. Llorens C, Schwartz JC. Enkephalinase activity in rat peripheral organs. Eur J Pharmacol 1981; 1: 113-116 (Pubitemid 11210305)
35. Schwartz JC, Malfroy B, De La BS. Biological inactivation of enkephalins and the role of enkephalin-dipeptidyl-carboxypeptidase (" enkephalinase") as neuropeptidase. Life Sci 1981; 17: 1715-1740
36. Kerr MA, Kenny AJ. The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J 1974; 3: 477-488
37. Matsas R, Kenny AJ, Turner AJ. The metabolism of neuropeptides. The hydrolysis of peptides, including enkephalins, tachykinins and their analogues, by endopeptidase-24.11. Biochem J 1984; 2: 433-440
38. Matsas R, Fulcher IS, Kenny AJ, Turner AJ. Substance P and [Leu]enkephalin are hydrolyzed by an enzyme in pig caudate synaptic membranes that is identical with the endopeptidase of kidney microvilli. Proc Natl Acad Sci USA 1983; 10: 3111-3115
39. Stephenson SL, Kenny AJ. Metabolism of neuropeptides. Hydrolysis of the angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar membranes. Biochem J 1987; 1: 237-247
40. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 2004; Pt 1: 45-51.
41. Koehn JA, Norman JA, Jones BN, LeSueur L, Sakane Y, Ghai RD. Degradation of atrial natriuretic factor by kidney cortex membranes. Isolation and characterization of the primary proteolytic product. J Biol Chem 1987; 24: 11623-11627
42. Zimmerman RS, Martinez AJ, MacPhee AA, Barbee RW. Atrial natriuretic factor blocks the pressor action of endothelin. J Cardiovasc Pharmacol 1990; 6: 865-870
43. Maki T, Horio T, Yoshihara F, Suga S, Takeo S, Matsuo H, et al. Effect of neutral endopeptidase inhibitor on endogenous atrial natriuretic peptide as a paracrine factor in cultured cardiac fibroblasts. Br J Pharmacol 2000; 6: 1204-1210 (Pubitemid 30953573)
44. Gafford JT, Skidgel RA, Erdos EG, Hersh LB. Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides. Biochemistry 1983; 13: 3265-3271
45. Matsas R, Turner AJ, Kenny AJ. Endopeptidase-24.11 and aminopeptidase activity in brain synaptic membranes are jointly responsible for the hydrolysis of cholecystokinin octapeptide (CCK-8). FEBS Lett 1984; 1: 124-128 (Pubitemid 14006530)
46. Roques BP, Fournie-Zaluski MC, Soroca E, Lecomte JM, Malfroy B, Llorens C, et al. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature 1980; 5788: 286-288 (Pubitemid 11165881)
47. Fulcher IS, Matsas R, Turner AJ, Kenny AJ. Kidney neutral endopeptidase and the hydrolysis of enkephalin by synaptic membranes show similar sensitivity to inhibitors. Biochem J 1982; 2: 519-522
48. Benchetrit T, Bissery V, Mornon JP, Devault A, Crine P, Roques BP. Primary structure homologies between two zinc metallopeptidases, the neutral endopeptidase 24.11 ("enkephalinase") and thermolysin, through clustering analysis. Biochemistry 1988; 2: 592-596
49. Devault A, Sales V, Nault C, Beaumont A, Roques B, Crine P, et al. Exploration of the catalytic site of endopeptidase 24.11 by site-directed mutagenesis. Histidine residues 583 and 587 are essential for catalysis. FEBS Lett 1988; 1: 54-58
50. Devault A, Nault C, Zollinger M, Fournie-Zaluski MC, Roques BP, Crine P, et al. Expression of neutral endopeptidase (enkephalinase) in heterologous COS-1 cells. Characterization of the recombinant enzyme and evidence for a glutamic acid residue at the active site. J Biol Chem 1988; 8: 4033-4040 (Pubitemid 18079002)
51. Hersh LB, Morihara K. Comparison of the subsite specificity of the mammalian neutral endopeptidase 24.11 (enkephalinase) to the bacterial neutral endopeptidase thermolysin. J Biol Chem 1986; 14: 6433-6437 (Pubitemid 17204154)
52. Bateman RC, Jr., Jackson D, Slaughter CA, Unnithan S, Chai YG, Moomaw C, et al. Identification of the active-site arginine in rat neutral endopeptidase 24.11 (enkephalinase) as arginine 102 and analysis of a glutamine 102 mutant. J Biol Chem 1989; 11: 6151-6157 (Pubitemid 19106684)
53. Dion N, Le Moual H, Fournie-Zaluski MC, Roques BP, Crine P, Boileau G. Evidence that Asn542 of neprilysin (EC 3.4.24.11) is involved in binding of the P2′ residue of substrates and inhibitors. Biochem J 1995; 311(Pt-2): 623-627
54. Marie-Claire C, Ruffet E, Antonczak S, Beaumont A, O'Donohue M, Roques BP, et al. Evidence by site-directed mutagenesis that arginine 203 of thermolysin and arginine 717 of neprilysin (neutral endopeptidase) play equivalent critical roles in substrate hydrolysis and inhibitor binding. Biochemistry 1997; 45: 13938-13945 (Pubitemid 27494902)
55. Le Moual H, Roques BP, Crine P, Boileau G. Substitution of potential metal-coordinating amino acid residues in the zinc-binding site of endopeptidase-24.11. FEBS Lett 1993; 2: 196-200. (Pubitemid 23170414)
56. Dion N, Le Moual H, Crine P, Boileau G. Kinetic evidence that His-711 of neutral endopeptidase 24.11 is involved in stabilization of the transition state. FEBS Lett 1993; 3: 301-304 (Pubitemid 23071757)
57. Tiraboschi G, Jullian N, Thery V, Antonczak S, Fournie-Zaluski MC, Roques BP. A three-dimensional construction of the active site (region 507-749) of human neutral endopeptidase (EC.3.4.24.11). Protein Eng 1999; 2: 141-149
58. Oefner C, D'Arcy A, Hennig M, Winkler FK, Dale GE. Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. J Mol Biol 2000; 2: 341-349 (Pubitemid 30700890)
59. Oefner C, Roques BP, Fournie-Zaluski MC, Dale GE. Structural analysis of neprilysin with various specific and potent inhibitors. Acta Crystallogr D Biol Crystallogr 2004; Pt 2: 392-396
60. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 6163: 411-415 (Pubitemid 18090241)
61. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 8: 2863-2867 (Pubitemid 19112640)
62. Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. J Biol Chem 1989; 25: 14954-14959 (Pubitemid 19237323)
63. Denault JB, Claing A, D'Orleans-Juste P, Sawamura T, Kido T, Masaki T, et al. Processing of proendothelin-1 by human furin convertase. FEBS Lett 1995; 3: 276-280
64. Barnes K, Murphy LJ, Takahashi M, Tanzawa K, Turner AJ. Localization and biochemical characterization of endothelin-converting enzyme. J Cardiovasc Pharmacol 1995; S37-S39.
65. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994; 3: 473-485
66. Morawietz H, Goettsch W, Szibor M, Barton M, Shaw S, Hakim K, et al. Increased expression of endothelin-converting enzyme-1 in failing human myocardium. Clin Sci (Lond) 2002; 237S-40S. (Pubitemid 35007160)
67. Zolk O, Quattek J, Sitzler G, Schrader T, Nickenig G, Schnabel P, et al. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation 1999; 16: 2118-2123 (Pubitemid 29196795)
68. Schunkert H, Orzechowski HD, Bocker W, Meier R, Riegger GA, Paul M. The cardiac endothelin system in established pressure overload left ventricular hypertrophy. J Mol Med 1999; 8: 623-630 (Pubitemid 29479983)
69. McMahon EG, Palomo MA, Moore WM. Phosphoramidon blocks the pressor activity of big endothelin[1-39] and lowers blood pressure in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1991; S29-S33.
70. Shimada K, Takahashi M, Turner AJ, Tanzawa K. Rat endothelin-converting enzyme-1 forms a dimer through Cys412 with a similar catalytic mechanism and a distinct substrate binding mechanism compared with neutral endopeptidase-24.11. Biochem J 1996; 863-867 (Pubitemid 26147614)
71. Hoang MV, Sansom CE, Turner AJ. Mutagenesis of Glu403 to Cys in rabbit neutral endopeptidase-24.11 (neprilysin) creates a disulphide-linked homodimer: analogy with endothelin-converting enzyme. Biochem J 1997; 925-929 (Pubitemid 27487703)
72. Johnson GD, Stevenson T, Ahn K. Hydrolysis of peptide hormones by endothelin-converting enzyme-1. A comparison with neprilysin. J Biol Chem 1999; 7: 4053-4058 (Pubitemid 129503041)
73. Sansom CE, Hoang MV, Turner AJ. Molecular modelling and site-directed mutagenesis of the active site of endothelin-converting enzyme. Protein Eng 1998; 12: 1235-1241 (Pubitemid 29012134)
74. Johnson GD, Swenson HR, Ramage R, Ahn K. Mapping the active site of endothelin-converting enzyme-1 through subsite specificity and mutagenesis studies: a comparison with neprilysin. Arch Biochem Biophys 2002; 2: 240-248 (Pubitemid 34848591)
75. Bur D, Dale GE, Oefner C. A three-dimensional model of endothelin-converting enzyme (ECE) based on the X-ray structure of neutral endopeptidase 24.11 (NEP). Protein Eng 2001; 5: 337-341
76. Schulz H, Dale GE, Karimi-Nejad Y, Oefner C. Structure of human endothelin-converting enzyme I complexed with phos-phoramidon. J Mol Biol 2009; 385(1): 178-187
77. Burnett JC, Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl 1999; 1: S37-S43.
78. Bralet J, Schwartz JC. Vasopeptidase inhibitors: an emerging class of cardiovascular drugs. Trends Pharmacol Sci 2001; 3: 106-109 (Pubitemid 32181837)
79. Northridge DB, Jardine AG, Alabaster CT, Barclay PL, Connell JM, Dargie HJ, et al. Effects of UK 69 578: a novel atriopeptidase inhibitor. Lancet 1989; 8663: 591-593
80. Favrat B, Burnier M, Nussberger J, Lecomte JM, Brouard R, Waeber B, et al. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1995; 7: 797-804.
81. Dussaule JC, Grange JD, Wolf JP, Lecomte JM, Gros C, Schwartz JC, et al. Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites. J Clin Endocrinol Metab 1991; 3: 653-659 (Pubitemid 21921744)
82. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993; 1: 87-146. (Pubitemid 23108243)
83. Gros C, Noel N, Souque A, Schwartz JC, Danvy D, Plaquevent JC, et al. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci USA 1991; 10: 4210-4214 (Pubitemid 21914509)
84. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977; 4288: 441-444 (Pubitemid 8073845)
85. Llorens C, Gacel G, Swerts JP, Perdrisot R, Fournie-Zaluski MC, Schwartz JC, et al. Rational design of enkephalinase inhibitors: substrate specificity of enkephalinase studied from inhibitory potency of various dipeptides. Biochem Biophys Res Commun 1980; 4: 1710-1716 (Pubitemid 11220013)
86. Flynn GA, Beight DW, Mehdi S, Koehl JR, Giroux EL, French JF, et al. Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11. J Med Chem 1993; 16: 2420-2423 (Pubitemid 23262477)
87. Robl JA, Sun CQ, Stevenson J, Ryono DE, Simpkins LM, Cimarusti MP, et al. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1997; 11: 1570-1577 (Pubitemid 27231460)
88. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998; 3 (Pt 1): 363-372 (Pubitemid 28186749)
89. Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension 2003; 3: 383-389
90. Campese VM, Lasseter KC, Ferrario CM, Smith WB, Ruddy MC, Grim CE, et al. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension 2001; 6: 1342-1348
91. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 2: 103-111 (Pubitemid 38125125)
92. Allikmets K. Aliskiren (Speedel). Curr Opin Investig Drugs 2002; 10: 1479-1482
93. Ozdener F, Ozdemir V. Fasidotril eli lilly. Curr Opin Investig Drugs 2003; 9: 1113-1119
94. Daull P, Jeng AY, Battistini B. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2007; 3: 247-256 (Pubitemid 47428971)
95. Tabrizchi R. Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs 2008; 3: 301-309 (Pubitemid 351323384)
96. Daull P, Benrezzak O, Arsenault D, Pheng LH, Blouin A, Cayer J, et al. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats. Am J Hypertens 2005; 12 Pt 1: 1606-1613 (Pubitemid 41814683)
97. Fink CA, Qiao Y, Berry CJ, Sakane Y, Ghai RD, Trapani AJ. New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11. J Med Chem 1995; 26: 5023-5030 (Pubitemid 26012257)
98. Fink CA, Moskal M, Firooznia F, Hoyer D, Symonsbergen D, Wei D, et al. Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1. Bioorg Med Chem Lett 2000; 17: 2037-2039 (Pubitemid 30663367)
99. Battistini B, Daull P, Jeng AY. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme. Cardiovasc Drug Rev 2005; 4: 317-330 (Pubitemid 43853854)
100. Acharya KR, Sturrock ED, Riordan JF, Ehlers MR. Ace revisited: a new target for structure-based drug design. Nat Rev Drug Discov 2003; 11: 891-902.
101. Ehlers MR. Safety issues associated with the use of angiotensin- converting enzyme inhibitors. Expert Opin Drug Saf 2006; 6: 739-740 (Pubitemid 44669486)
102. Georgiadis D, Beau F, Czarny B, Cotton J, Yiotakis A, Dive V. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ Res 2003; 2: 148-154 (Pubitemid 36919702)
103. van Esch JH, van Gool JM, de Bruin RJ, Payne JR, Montgomery HE, Hectors M, et al. Different contributions of the angiotensin-converting enzyme C-domain and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype. J Hypertens 2008; 4: 706-713 (Pubitemid 351354918)
104. Fink CA, Carlson JE, McTaggart PA, Qiao Y, Webb R, Chatelain R, et al. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin- converting enzyme and neutral endopeptidase. J Med Chem 1996; 16: 3158-3168 (Pubitemid 26260321)
105. De Lombaert S, Blanchard L, Stamford LB, Tan J, Wallace EM, Satoh Y, et al. Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action. J Med Chem 2000; 3: 488-504. (Pubitemid 30102089)
106. Dive V, Jullien N, Scalbert E, Yiotakis A, Makaritis A. 2006; patent WO/2006/092495.
107. Hernandez Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008; 5: 1312-1317 (Pubitemid 351555943)
108. Borradaile NM, Pickering JG. NAD(+), sirtuins, and cardiovascular disease. Curr Pharm Des 2009; 15(1): 110-117
109. Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm Des 2008; 14(10): 979-986
110. Nichols WW, Epstein BJ. Actions of selected cardiovascular hormones on arterial stiffness and wave reflections. Curr Pharm Des 2009; 15(3): 304-320